Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Genetic variants play a role in modulating the risk of drug-induced ventricular arrhythmias, highlighting the potential for pharmacogenetic approaches to improve drug safety.
Ventricular arrhythmia induced by drugs (pro-arrythmia) is an uncommon event, whose occurrence is unpredictable but potentially fatal. The ability of a variety of medications to induce these arrhythmias is a significant problem facing the pharmaceutical industry. Genetic variants have been shown to play a role in adverse events and are also known to influence an individual's optimal drug dose. This review provides an overview of the current understanding of the role of genetic variants in modulating the risk of drug induced arrhythmias.
No takes yet. Share an insight, caveat, or question.
Petropoulou et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: